Hello,
We have a few updates to share regarding the recent NCCN Guidelines updates.
- Sharing a new Prolaris piece with you which discusses how the simon criteria is not the same as NCCN evidence. It is accessible on the marketing website under the competitive section for GPS.
- Paul Blair was kind enough to share recent physician feedback regarding the recent NCCN update from an academic urologist at Brown Urology in Rhode Island over the past week or so. The physician brought the topic up to him, noting that none of the biomarkers were indicated in the low-risk space, noting it is a more even playing field from that perspective.
And as you all know, GPS excels in a low-risk space due to the test design and validations.
We want to thank Paul for sharing this story with us, and we encourage you to reach out to marketing@mdxhealth.comwith any feedback you hear from the field, positive or otherwise.
- We are working on creation of a literature piece to address the recent change if and when conversations arise. You can expect it to be available after the turn of the year. We will keep you posted as it becomes available.
Marketing
